Literature DB >> 20587489

Vitamin B12-responsive severe leukoencephalopathy and autonomic dysfunction in a patient with "normal" serum B12 levels.

J J Graber1, F T Sherman, H Kaufmann, E H Kolodny, S Sathe.   

Abstract

Leukoencephalopathy and autonomic dysfunction have been described in individuals with very low serum B(12) levels (<200 pg/ml), in addition to psychiatric changes, neuropathy, dementia and subacute combined degeneration. Elevated homocysteine and methylmalonic acid levels are considered more sensitive and specific for evaluating truly functional B(12) deficiency. A previously healthy 62-year-old woman developed depression and cognitive deficits with autonomic dysfunction that progressed over the course of 5 years. The patient had progressive, severe leukoencephalopathy on multiple MRI scans over 5 years. Serum B(12) levels ranged from 267 to 447 pg/ml. Homocysteine and methylmalonic acid levels were normal. Testing for antibody to intrinsic factor was positive, consistent with pernicious anaemia. After treatment with intramuscular B(12) injections (1000 μg daily for 1 week, weekly for 6 weeks, then monthly), she made a remarkable clinical recovery but remained amnesic for major events of the last 5 years. Repeat MRI showed partial resolution of white matter changes. Serum B(12), homocysteine and methylmalonic acid levels are unreliable predictors of B(12)-responsive neurologic disorders, and should be thoroughly investigated and presumptively treated in patients with unexplained leukoencephalopathy because even long-standing deficits may be reversible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587489     DOI: 10.1136/jnnp.2009.178657

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

Review 2.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

3.  Functional cobalamin (vitamin B12) deficiency: role of advanced age and disorders associated with increased oxidative stress.

Authors:  L R Solomon
Journal:  Eur J Clin Nutr       Date:  2015-01-07       Impact factor: 4.016

4.  Inhaled Nitrous Oxide 'Whip-Its!' Causing Subacute Combined Degeneration of Spinal Cord.

Authors:  Mohammed Al-Sadawi; Hidalgo Claris; Chinyere Archie; Apoorva Jayarangaiah; Modupe Oluya; Samy I McFarlane
Journal:  Am J Med Case Rep       Date:  2018-12-26

5.  Subacute combined degeneration of the spinal cord following recreational nitrous oxide use.

Authors:  Hui Mei Cheng; Jae Hong Park; David Hernstadt
Journal:  BMJ Case Rep       Date:  2013-03-08

6.  Diabetes as a cause of clinically significant functional cobalamin deficiency.

Authors:  Lawrence R Solomon
Journal:  Diabetes Care       Date:  2011-03-18       Impact factor: 19.112

Review 7.  The Many Faces of Cobalamin (Vitamin B12) Deficiency.

Authors:  Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-05-27

8.  Subacute combined degeneration: a case of pernicious anaemia without haematological manifestations.

Authors:  Matthew R Lavoie; Nicolette C Cohen; Timothy A Gregory; Peter V Weber
Journal:  BMJ Case Rep       Date:  2020-03-24

Review 9.  Cobalamin deficiency: clinical picture and radiological findings.

Authors:  Chiara Briani; Chiara Dalla Torre; Valentina Citton; Renzo Manara; Sara Pompanin; Gianni Binotto; Fausto Adami
Journal:  Nutrients       Date:  2013-11-15       Impact factor: 5.717

10.  Uncommon manifestations of Vitamin B12 deficiency.

Authors:  Rabindra N Mohapatra; Sudhi R Pradhan; Pushpa Kumari
Journal:  Indian J Psychiatry       Date:  2018 Apr-Jun       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.